At the 2nd Annual Kymanox Showcase, powered by Seed2Table Life Science, founders presented technologies addressing challenges across multiple life science modalities. Collectively, these companies raised more than $25 million in the past year while operating with lean, hypervirtual teams. All of the participating founders and teams are operating leaner, moving faster, and tackling highly complex problems precisely because they’ve embraced the Kymanox Hyper-Virtual Model™.
Eight presenting companies took the stage, each representing a distinct frontier of innovation. Collectively, their work spanned corneal repair, cancer immunotherapy adjuvants, non-invasive glucose monitoring, topical vascular anomaly treatments, buffered dental anesthetics, on- demand drug reconstitution, sterilization sensing, and automated emergency medication delivery. These were not early incubator-stage concepts. They are companies advancing toward meaningful inflection points, raising capital, and preparing for clinical and commercial execution. These companies included:
- MedPhlow
- Clarus Biologics
- SterilMetric
- Orbio
- Balanced Pharma
- Arkayli
- BioLattice
- Solution Medical
Stephen Perry, Kymanox Co-Founder, and other speakers repeatedly highlighted how the model allows startups to outsource everything except vision, decision-making, and accountability. Instead of building large internal teams burdened by expensive investments into human capital, infrastructure, and overhead, founders activate small, capable “tiger teams” of experts on demand — from regulatory affairs and engineering to project management and manufacturing strategy.
The results shared onstage were striking:
- One founder noted they checked off ~20 of the 25 hardest milestones to reach market, with the remaining steps feeling far more manageable.
- Another credited the model with delivering their product $3 million under budget and 18 months ahead of schedule.
- Multiple teams described accessing world-class sterilization expertise, precise implant engineering, combination product development, and FDA navigation without the cash burn of full-time hires.
- Several returning “Class of 2025” companies reported raising well over $25 million collectively in the past year while staying lean — a testament to how the model helps attract sophisticated capital by demonstrating efficient execution.
Todd Wallach of Solution Medical captured the spirit perfectly, describing how the hyper-virtual approach lets small teams stay mission-focused and culturally aligned, avoiding the dilution of culture that often comes with rapid hiring. Eric Edwards of Phlow, and spin-out MedPhlow, echoed this, noting seamless execution on complex delivery systems and human factors work while keeping their core team extremely small.
Kymanox’s deep bench, including rare sterilization specialists and regulatory practitioners, who are among 300 experts working at the firm, gives these startups access to capabilities that would otherwise require years and millions to build internally. As one speaker put it, the model turns Kymanox into a flexible extension of the founding team, providing precision without the bloat.
In an industry where development timelines are long, regulatory hurdles are high, and capital efficiency is everything, the Hyper-Virtual Model is proving to be a genuine differentiator. Founders aren’t just surviving — they’re accelerating toward clinical milestones, GMP readiness, and commercial inflection points with far less friction.
The Showcase itself embodied this philosophy: an intimate, high-impact evening at The Umstead Hotel and Spa where curated conversations replaced standard pitches, mirroring the efficient, relationship-driven ethos that powers the model.
The life sciences industry is under increasing pressure to bring ever more complex products to market faster. Timelines matter, capital efficiency matters, and delays carry real consequences. The winners may not be the companies with the biggest teams or deepest war chests. They may be the lean, focused teams smart enough to stay hyper-virtual and partner with the right expertise at the right time. Kymanox supports this reality because patients deserve better.
At a time when raising capital is essential to continued progress, the companies featured at the Showcase demonstrated what disciplined execution looks like today. These teams showed how focused development, credible milestones, and efficient use of expertise can keep programs moving forward in a challenging funding environment.
